Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

Date publication

avril 2026

Journal

ESMO open

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KAMINSKY Marie-Christine , Dr BURGY Mickaël

Tous les auteurs :
Fayette J, Cropet C, Toullec C, Burgy M, Bruyas A, Sire C, Lagrange A, Clatot F, Vinches M, Iacob M, Martin L, Kaminsky MC, Vansteene D, Salas S, Champagnac A, Saintigny P, Gautier J, Pérol D, Bourhis J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41962312

Résumé

Pembrolizumab, combined with platinum-5-FU or as a monotherapy, is the standard treatment of patients with recurrent and/or metastatic (R/M) head and neck squamous-cell carcinoma (HNSCC). This treatment is used exclusively in programmed death-ligand 1 (PD-L1)-positive patients in Europe, whereas it is used in the USA regardless of PD-L1 status. However, substantial toxicities, notably those related to cisplatin-based chemotherapy, preclude the use of combination therapy in fragile patients. We investigated the efficacy and tolerance of first-line durvalumab combined with weekly carboplatin/paclitaxel in R/M HNSCC patients who were ineligible for cisplatin.

Mots clés

carboplatin, cisplatin ineligibility, immunotherapy, paclitaxel, recurrent and/or metastatic head and neck squamous-cell carcinoma (R/M HNSCC), weekly chemotherapy

Référence

ESMO Open. 2026 04 9;11(4):106946